GILD Stock Analysis: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
$139.33
-0.97 (-0.69%)
▼
5d:
+1.79%
30d:
-6.0%
90d:
+13.52%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 23, 2026
20d
Smart Money Accumulation
GILD is down 3.2% this week, but smart money is accumulating calls. Top strike: $150 2026-04-17 with 3,114 OI. Call ratio: 67% View Scanner →
Strength: 3.3/10
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GILD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GILD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$205.54
Based on 7.5% avg growth
INTRINSIC VALUE TODAY
$127.63
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GILD is currently trading at $139.33, which is considered slightly low relative to its 30-day fair value range of $138.70 to $147.79. The stock's valuation (Forward PE: 14.6) is in line with its historical norms (14.9). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 23.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GILD is in a strong uptrend. The price is approaching resistance at $141.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GILD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $157.43 (+12.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GILD is in a strong uptrend. The price is approaching resistance at $141.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GILD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $157.43 (+12.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$138.70 -
$147.79
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding GILD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($157.43)
Fair Price Analysis
30-Day Fair Range
$138.70 -
$147.79
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$133.89
Resistance Level
$141.70
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.58
Wall Street Target
$157.43
(+12.2%)
Revenue Growth (YoY)
4.7%
Earnings Growth (YoY)
23.4%
Profit Margin
28.9%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
14.6 vs 14.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$139.32
(-1%)
2-Year Target
$138.34
(-1%)
3-Year Target
$137.37
(-2%)
3-Yr Target (if PE normalizes)
(PE: 15→15)
$140.37
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 11.0%)
$294.10
(+110%)
Base:
(SPY PE: 14.6, Growth: 11.0%)
$191.88
(+37%)
Bear:
(PE: 12.4, Growth: 11.0%)
$163.10
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 20.24 | Current EPS (TTM): $6.78
Bull Case
$214.04
(+56%)
Analyst growth 41.8%, PE expands to 22.3
Base Case
$194.58
(+42%)
Market implied 41.8%, PE stable at 20.2
Bear Case
$93.30
(-32%)
Severe decline -20.0%, PE contracts to 17.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.6 to 14.9
Stabilization Target:
$143.36
(+2.2%)
PE Expansion Potential:
+2.2%
Share & Embed Analysis
Last updated: April 02, 2026 12:28 PM ET
Data refreshes hourly during market hours. Next update: 1:28 PM
Data refreshes hourly during market hours. Next update: 1:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GILD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew D Dickinson
SELL
3000 shares
2026-03-16
Johanna Mercier
SELL
3000 shares
2026-03-16
Daniel Patrick O'day
SELL
10000 shares
2026-02-27
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 57 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$128 | 59 HOLD |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
